Summary

Psychiatric patients are often vulnerable physically, and studies show low rates of monitoring for side effects in patients taking second-generation antipsychotics (SGAs). This article discusses results of a study that used an online survey and interviews to investigate the barriers to monitoring patients for the side effects of SGAs.